Differentially expressed proteins in human breast cancer cells sensitive and resistant to paclitaxel
- Authors:
- Nela Pavlikova
- Irena Bartonova
- Lucia Dincakova
- Petr Halada
- Jan Kovar
-
Affiliations: Department of Cellular and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic , Laboratory of Molecular Structure Characterization, Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic - Published online on: June 3, 2014 https://doi.org/10.3892/ijo.2014.2484
- Pages: 822-830
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Jordan MA: Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2:1–17. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA and Parissenti AM: cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat. 96:17–39. 2006. View Article : Google Scholar | |
|
Galletti E, Magnani M, Renzulli ML and Botta M: Paclitaxel and docetaxel resistance: Molecular mechanisms and development of new generation taxanes. Chem Med Chem. 2:920–942. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Stordal B and Davey R: A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1. Curr Cancer Drug Targets. 9:354–365. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B and Szczylik C: The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol. 68:553–557. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vergara D, Tinelli A, Iannone A and Maffia M: The impact of proteomics in the understanding of the molecular basis of paclitaxel-resistance in ovarian tumors. Curr Cancer Drug Targets. 12:987–997. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rebucci M and Michiels C: Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 85:1219–1226. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mechetner E, Kyshtoobayeva A, Zonis S, et al: Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res. 4:389–398. 1998.PubMed/NCBI | |
|
Pires MM, Emmert D, Hrycyna CA and Chmielewski J: Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol. 75:92–100. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Thollet A, Vendrell JA, Payen L, et al: ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Mol Cancer. 9:2912010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Chen QF, Jin S, et al: Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells. Scand J Gastroenterol. 47:802–808. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kwak JO, Lee SH, Lee GS, et al: Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol. 627:92–98. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH and Schinkel AH: MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 116:824–829. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
O’Brien C, Cavet G, Pandita A, et al: Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 68:5380–5389. 2008.PubMed/NCBI | |
|
Violini S, D’Ascenzo S, Bagnoli M, et al: Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line. J Exp Clin Cancer Res. 23:83–91. 2004.PubMed/NCBI | |
|
Takano M, Otani Y, Tanda M, Kawami M, Nagai J and Yumoto R: Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2. Drug Metab Pharmacokinet. 24:418–427. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kars MD, Iseri OD and Gunduz U: A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells. Eur J Pharmacol. 657:4–9. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Taniguchi R, Kumai T, Matsumoto N, et al: Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci. 97:83–90. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia-Martin E, Pizarro RM, Martinez C, et al: Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P4502C8. Pharmacogenomics. 7:575–585. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hendrikx J, Lagas JS, Rosing H, Schellens JHM, Beijnen JH and Schinkel AH: P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer. 132:2439–2447. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Henningsson A, Sparreboom A, Sandstrom M, et al: Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer. 39:1105–1114. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
De Hoon JPJ, Veeck J, Vriens B, Calon TGA, van Engeland M and Tjan-Heijnen VCG: Taxane resistance in breast cancer: A closed HER2 circuit? Biochim Biophys Acta Rev Cancer. 1825:197–206. 2012.PubMed/NCBI | |
|
Arai T, Miyoshi Y, Kim SJ, et al: Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol. 34:734–738. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jardim BV, Moschetta MG, Gelaleti GB, et al: Glutathione transferase pi (GSTpi) expression in breast cancer: An immunohistochemical and molecular study. Acta Histochem. 114:510–517. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Miyake T, Nakayama T, Naoi Y, et al: GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci. 103:913–920. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ferlini C, Raspaglio G, Mozzetti S, et al: Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol. 64:51–58. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Pan Z and Gollahon L: Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calcium release in a dosage dependent manner. Biochem Biophys Res Commun. 432:431–437. 2013. View Article : Google Scholar | |
|
Ali-Osman F, Brunner JM, Kutluk TM and Hess K: Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res. 3:2253–2261. 1997.PubMed/NCBI | |
|
Cheung CHA, Wu SY, Lee TR, et al: Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes. PLoS One. 5:e125642010. View Article : Google Scholar | |
|
Wang YH, Sparano JA, Fineberg S, et al: High expression of class III beta-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. Clin Breast Cancer. 13:103–108. 2013. View Article : Google Scholar | |
|
Yin SH, Zeng CQ, Hari M and Cabral F: Random mutagenesis of beta-tubulin defines a set of dispersed mutations that confer paclitaxel resistance. Pharm Res. 29:2994–3006. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Edelman MJ and Shvartsbeyn M: Epothilones in development for non-small-cell lung cancer: Novel anti-tubulin agents with the potential to overcome taxane resistance. Clin Lung Cancer. 13:171–180. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Diaz JF, Barasoain I and Andreu JM: Fast kinetics of taxol binding to microtubules. Effects of solution variables and microtubule-associated proteins. J Biol Chem. 278:8407–8419. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Mukherjee N, Bermudez RS, et al: Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 64:293–302. 2005. View Article : Google Scholar | |
|
Wang S, Huang X, Lee CK and Liu B: Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of survivin. Oncogene. 29:4225–4236. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lv KZ, Liu LQ, Wang LB, et al: Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS One. 7:e400082012. View Article : Google Scholar : PubMed/NCBI | |
|
Lu MS, Xiao L, Hu JL, Deng S and Xu Y: Targeting of p38 mitogen-activated protein kinases to early growth response gene 1 (EGR-1) in the human paclitaxel-resistance ovarian carcinoma cells. J Huazhong Univ Sci Tech-Med. 28:451–455. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Arai K, Matsumoto Y, Nagashima Y and Yagasaki K: Regulation of class II beta-tubulin expression by tumor suppressor p53 protein in mouse melanoma cells in response to vinca alkaloid. Mol Cancer Res. 4:247–255. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Farrell A: A close look at cancer. Nat Med. 17:262–265. 2011. View Article : Google Scholar | |
|
Pan Z, Gao YL, Heng LS, et al: Amphiphilic N-(2,3-dihydroxypropyl)-chitosan-cholic acid micelles for paclitaxel delivery. Carbohydr Polym. 94:394–399. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ehrlichova M, Koc M, Truksa J, Naldova Z, Vaclavikova R and Kovarr J: Cell death induced by taxanes in breast cancer cells: Cytochrome c is released in resistant but not in sensitive cells. Anticancer Res. 25:4215–4224. 2005.PubMed/NCBI | |
|
Ehrlichova M, Ojima I, Chen J, et al: Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells. Naunyn-Schmiedebergs Arch Pharmacol. 385:1035–1048. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nemcova-Furstova V, Balusikova K, Sramek J, James RF and Kovar J: Caspase-2 and JNK activated by saturated fatty acids are not involved in apoptosis induction but modulate ER stress in human pancreatic beta-cells. Cell Physiol Biochem. 31:277–289. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dyballa N and Metzger S: Fast and sensitive colloidal coomassie G-250 staining for proteins in polyacrylamide gels. J Vis Exp. 30:1–5. 2009.PubMed/NCBI | |
|
Jelinek M, Balusikova K, Kopperova D, et al: Caspase-2 is involved in cell death induction by taxanes in breast cancer cells. Cancer Cell Int. 13:422013. View Article : Google Scholar | |
|
Vidalino L, Doria A, Quarta S, Zen M, Gatta A and Pontisso P: Serpin B3, apoptosis and autoimmunity. Autoimmun Rev. 9:108–112. 2009. View Article : Google Scholar | |
|
Ho KY, Huang HH, Hung KF, et al: Cholesteatoma growth and proliferation: Relevance with serpin B3. Laryngoscope. 122:2818–2823. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gettins PGW: Serpin structure, mechanism, and function. Chem Rev. 102:4751–4803. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Izuhara K, Ohta S, Kanaji S, Shiraishi H and Arima K: Recent progress in understanding the diversity of the human ov-serpin/clade B serpin family. Cell Mol Life Sci. 65:2541–2553. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cataltepe S, Gornstein ER, Schick C, et al: Co-expression of the squamous cell carcinoma antigens 1 and 2 in normal adult human tissues and squamous cell carcinomas. J Histochem Cytochem. 48:113–122. 2000.PubMed/NCBI | |
|
Murakami A, Suminami Y, Hirakawa H, Nawata S, Numa F and Kato H: Squamous cell carcinoma antigen suppresses radiation-induced cell death. Br J Cancer. 84:851–858. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Suminami Y, Nagashima S, Murakami A, et al: Suppression of a squamous cell carcinoma (SCC)-related serpin, SCC antigen, inhibits tumor growth with increased intratumor infiltration of natural killer cells. Cancer Res. 61:1776–1780. 2001. | |
|
Collie-Duguid ESR, Sweeney K, Stewart KN, Miller ID, Smyth E and Heys SD: SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 132:807–818. 2011. View Article : Google Scholar | |
|
Lim W, Kim HS, Jeong W, et al: Serpin B3 in the chicken model of ovarian cancer: A prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer. Plos One. 7:e498692012. View Article : Google Scholar : PubMed/NCBI | |
|
Kerr KM: Personalized medicine for lung cancer: new challenges for pathology. Histopathology. 60:531–546. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Felbor U, Dreier L, Bryant RAR, Ploegh HL, Olsen BR and Mothes W: Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 19:1187–1194. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo T, Kigoshi H, Hagiwara T, Takino T, Yamazaki M and Yui S: Cathepsin G, a neutrophil protease, induces compact cell-cell adhesion in MCF-7 human breast cancer cells. Mediat Inflamm. 2009:8509402009. View Article : Google Scholar : PubMed/NCBI | |
|
Lankelma JM, Voorend DM, Barwari T, et al: Cathepsin L, target in cancer treatment? Life Sci. 86:225–233. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Small DM, Burden RE, Jaworski J, et al: Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization. Int J Cancer. 133:2102–2112. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FAE and Giaccone G: Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res. 64:27–30. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
De Koning PJA, Kummer JA, de Poot SAH, et al: Intracellular serine protease inhibitor serpin B4 inhibits granzyme M-induced cell death. PLoS One. 6:e226452011.PubMed/NCBI | |
|
Ahmed ST and Darnell JE: Serpin B3/B4, activated by STAT3, promote survival of squamous carcinoma cells. Biochem Biophys Res Commun. 378:821–825. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ehrnsperger M, Graber S, Gaestel M and Buchner J: Binding of nonnative protein to Hsp25 during heat shock creates a reservoir of folding intermediates for reactivation. EMBO J. 16:221–229. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Schmitt E, Gehrmann M, Brunet M, Multhoff G and Garrido C: Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol. 81:15–27. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP and Solary E: HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J. 13:2061–2070. 1999.PubMed/NCBI | |
|
Havasi A, Li ZJ, Wang ZY, et al: Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem. 283:12305–12313. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ciocca DR, Arrigo AP and Calderwood SK: Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch Toxicol. 87:19–48. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Weng YR, Cui Y and Fang JY: Biological functions of cytokeratin 18 in cancer. Mol Cancer Res. 10:485–493. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Galarneau L, Loranger A, Gilbert S and Marceau N: Keratins modulate hepatic cell adhesion, size and G1/S transition. Exp Cell Res. 313:179–194. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Abreu MT, Arnold ET, Chow JYC and Barrett KE: Phosphatidylinositol 3-kinase-dependent pathways oppose Fas-induced apoptosis and limit chloride secretion in human intestinal epithelial cells. Implications for inflammatory diarrheal states. J Biol Chem. 276:47563–47574. 2001. View Article : Google Scholar | |
|
Fortier AM, Van Themsche C, Asselin E and Cadrin M: Akt isoforms regulate intermediate filament protein levels in epithelial carcinoma cells. FEBS Lett. 584:984–988. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Inada H, Izawa I, Nishizawa M, et al: Keratin attenuates tumor necrosis factor-induced cytotoxicity through association with TRADD. J Cell Biol. 155:415–425. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Meng YG, Wu ZQ, Yin XY, et al: Keratin 18 attenuates estrogen receptor alpha-mediated signaling by sequestering LRP16 in cytoplasm. BMC Cell Biol. 10:962009. View Article : Google Scholar : PubMed/NCBI | |
|
Woelfle U, Sauter G, Santjer S, Brakenhoff R and Pantel K: Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res. 10:2670–2674. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Schaller G, Fuchs I, Pritze W, et al: Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res. 2:1879–1885. 1996.PubMed/NCBI |
